NeuroBo Submits IND Application For Phase 1 Clinical Trial Of DA-1726; Stock Up In Pre-market

(RTTNews) - NeuroBo Pharmaceuticals, Inc. (NRBO), a clinical-stage biotechnology company, Thursday said it has submitted Investigational New Drug or IND application to FDA, regarding Phase 1 clinical trial of DA-1726 for the treatment of obesity.

Obesity is an abnormal or excessive accumulation of fats that poses a risk to health.

Following this announcement, NeuroBo's stock surged 4.55%, to $3.45 in the pre-market period on the Nasdaq.

Phase 1 trial is a randomized, placebo-controlled, double-blind, sequential parallel group study to analyse the reaction of DA-1726 in obese subjects. The primary endpoint includes assessing safety and tolerability of DA-1726, while the secondary endpoint includes serum concentrations and metabolite profiling of highest does of DA-1726.

Also, exploratory endpoints consist of effect of DA-1726 on metabolic parameters, cardiac parameters, fasting lipid levels, body weight, waist circumference and body mass index (BMI).

The company said that preclinical data of DA-1726 shows that it reduces food intake as well as increases energy expenditure, resulting in persistent weight-loss.